HSCS

HeartSciencesF

Nasdaq / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$4.50

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$1.20

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$0.35

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Sentiment remains cautious-to-negative. The primary-source record confirms a real regulatory catalyst, but the stronger near-term fact pattern is balance-sheet stress: the 10-Q says current cash is insufficient for the next twelve months and raises substantial doubt about going concern, while the 8-K only reassures that the COO's passing should not change current commercialization plans [#10-Q-2026-03-16] [#8-K-2026-04-03]. This looks more like a monitoring situation than a high-conviction bullish setup.

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30catalystFinancing overhang and dilution risk stays front-and-centerHigh impact

The January 31, 2026 10-Q says existing cash is insufficient to fund the next twelve months, notes substantial doubt about going concern, and shows reliance on the ATM and Streeterville financing; any new raise or more aggressive note-related conversions would likely pressure the stock [#10-Q-2026-03-16].

2026-09-30eventFDA review outcome on MyoVista wavECG 510(k) submissionHigh impact

HeartSciences disclosed that it submitted the MyoVista wavECG device to the FDA on December 15, 2025, and the April 2026 8-K said commercialization plans remain unchanged after the COO's death; a clearance decision is the cleanest upside trigger, but timing remains uncertain [#10-Q-2026-03-16] [#8-K-2026-04-03].

2027-03-31catalystProof of commercial uptake for MyoVista Insights platformHigh impact

The 10-Q says MyoVista Insights launched in mid-2025 and is intended to support clinical workflow while the company continues development and commercialization, but no strong adoption proof is yet disclosed; any credible customer/revenue traction would help de-risk the story over time [#10-Q-2026-03-16].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology